(Q28279209)

https://api.crossref.org/works/10.1002%2FEJI.200636914

BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636914

B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636914

TNF Deficiency Fails to Protect BAFF Transgenic Mice against Autoimmunity and Reveals a Predisposition to B Cell Lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636914

Maturation of marginal zone and follicular B cells requires B cell activating factor of the tumor necrosis factor family and is independent of B cell maturation antigen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636914

7 January 2021

BAFF selectively enhances the survival of plasmablasts generated from human memory B cells.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636914

7 January 2021

Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636914

7 January 2021

BCMA is essential for the survival of long-lived bone marrow plasma cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636914

7 January 2021

Structures of APRIL-receptor complexes: like BCMA, TACI employs only a single cysteine-rich domain for high affinity ligand binding

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636914

7 January 2021

Identification of proteoglycans as the APRIL-specific binding partners.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636914

7 January 2021

Selective activation of TACI by syndecan-2

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636914

7 January 2021

NF-AT activation induced by a CAML-interacting member of the tumor necrosis factor receptor superfamily

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636914

7 January 2021

TACI attenuates antibody production costimulated by BAFF-R and CD40

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636914

7 January 2021

Regulation of the T-independent humoral response by TACI

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636914

7 January 2021

Activation and accumulation of B cells in TACI-deficient mice

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636914

7 January 2021

Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636914

7 January 2021

DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636914

7 January 2021

TACI and BAFF-R mediate isotype switching in B cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636914

7 January 2021

Impaired IgA class switching in APRIL-deficient mice

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636914

7 January 2021

Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636914

7 January 2021

TACI is mutant in common variable immunodeficiency and IgA deficiency

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200636914

7 January 2021